PHP33 An Overview of the Biosimilar Market in the Us  by Young, K.E. et al.
A410  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
PHP32
ImPact of HealtH PolIcy cHanges on tHe growtH locally 
manufactured and ImPorted PHarmaceutIcal markets In turkey
Hilal Vural E.1, Kockaya G.2, Yenilmez F.B.3, Saylan M.2, Safak Yilmaz E.1, Tatar M.3, Vural I.M.1, 
Akbulat A.1, Gursoz H.1, Artiran G.1, Kerman S.1
1Turkish Medicines and Medical Devices Agency, Ankara, Turkey, 2Health Economics and Policy 
Association, Ankra, Turkey, 3Hacettepe University, Ankara, Turkey
Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of health 
including pharmaceutical sales by improving access to health services. The objective 
of this analysis is to to understand the impact of selected 5 major policy changes 
by MoH to sales of locally manufactured and imported pharmaceutical products in 
the respective periods. MethOds: 132 months sales data with segmented regres-
sion analysis for interrupted time series were used. International reference pricing 
of pharmaceuticals (RF), mandatory reimbursement dossier submission for new 
molecules, new indications and line extensions with medical and economic evalu-
ations (MRDS), auditing for good manufacturing practice (GMP), family physician 
system (FP) and compulsory medical service for physicians (CMS) were selected as 
five major policies that may affect cost, demand and supply of pharmaceuticals. 
The analysis was conducted for total imported pharmaceutical (IP) sales and total 
locally manufactured pharmaceutical (LMP) sales. The Durbin-Watson d statistics 
of SPSS version 20.0 was used as serial correlation. Shift in slope with p< 0.05 was 
considered as statistically significant. Results: The negative effect of RF policy 
change on CS trends was more prominent for IP than LMP sales. However, the shift 
in CS due to other 4 policy changes was lower for IP when compared with LMP 
sales. The differences reached statistical significance level except for CMS policy. 
Although not significant, positive shift of US due to RF policy change was higher for 
LMP than IP sales. There was a decreasing slope of LMP unit sales following MRDS 
and GMP policies but an increasing slope of IP unit sales. cOnclusiOns: Policy 
changes may effect at differently direction and amount the unit and cost sales 
of LMPs and IPs. Cost control mechnism such as RF has a more negative effect on 
imported product as expected.
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Objectives: This study intends to provide an overview of the US biosimilar poli-
cies and its impact on the development of the biosimilar market in this coun-
try. MethOds: A literature review was conducted from the US Food and Drug 
Administration (FDA) website, Generics and Biosimilars Initiative (GaBi) web-
sites, Medline® database, and available grey literature. Results: The Biologics 
Price Competition and Innovation Act (2009) established an abbreviated Biologic 
License Application (aBLA) pathway/351 (k) for biosimilars in addition to the 1. 
Non-abbreviated biologic license application (BLA) /351 (a); 2. New Drug Application 
(NDA) /505 (b) (2); or 3. Abbreviated New Drug Application (ANDA). 10 follow-on 
biologics under NDA/ANDA and one under BLA were previously approved. Product 
identity and therapeutic equivalence of some biologics (i. e. Lovenox, Copaxone) led 
to important debates for defining the application pathway. Currently, the FDA has no 
351 (k) approvals. The lack of clear FDA guidance on data requirements for biosimi-
larity in aBLA was a limiting factor for manufacturers to go through aBLA pathway. 
They preferably opted for a classical BLA pathway due to its longer exclusivity period 
and nearly the same amount of data required (i. e. Neutroval). The impact of the 
recently released FDA draft guidance on designing clinical studies for biosimilar-
ity (5/13/14) is yet to be seen but should address issues on proving biosimilarity 
in aBLA. Further debate is anticipated but an increase in applications is expected 
and biosimilars savings are projected at $250 billion by 2024. cOnclusiOns: 
The biosimilars market is still lagging, specifically compared to the EU, with no 
351 (k) approvals despite the US’ leading position in the biopharmaceuticals market. 
However, the US’ high prices for innovative products and history of generic utiliza-
tion can signify a positive market projection after a transition period, as was seen 
in Germany and Sweden. Further, the new FDA guidance by addressing biosimilarity 
issues may ease biosimilar market entry.
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Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of health 
including pharmaceutical sales by improving access to health services. Total phar-
maceutical market reached US $ 8 billion in last 10 years. The objective of this 
analysis is to understand the impact of selected 5 major policy changes by MoH 
on the growth locally manufactured and imported pharmaceutical markets of top 
selling ATC1 phramaceutical group, which was Alimentary and Metabolism (A0) 
with US $ 1.1 billion sales in 2012, in the respective periods in Turkey. MethOds: 
132 months sales data with segmented regression analysis for interrupted time 
series were used. International reference pricing of pharmaceuticals (RF), manda-
tory reimbursement dossier submission for new molecules, new indications and 
line extensions with medical and economic evaluations (MRDS), auditing for good 
manufacturing practice (GMP), family physician system (FP) and compulsory medi-
cal service for physicians (CMS) were selected as five major policies that may affect 
cost, demand and supply of pharmaceuticals. We analyzed possible breaks in trends 
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Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of 
health including pharmaceutical sales by improving access to health services. 
Total pharmaceutical market reached US $ 8 billion in last 10 years. The objective 
of this study is to understand the differences in the impact of selected 5 policies 
on 5 top selling ATC1 groups in terms of cost sales (CS) in the respective peri-
ods. MethOds: 132 months sales data with segmented regression analysis for 
interrupted time series were used. International reference pricing of pharmaceu-
ticals (RF), mandatory reimbursement dossier submission for new molecules, new 
indications and line extensions with medical and economic evaluations (MRDS), 
auditing for good manufacturing practice (GMP), family physician system (FP) 
and compulsory medical service for physicians (CMS) were selected as five major 
policies that may affect cost, demand and supply of pharmaceuticals. We analyzed 
possible breaks in trends prior and after the implementation of 5 selected policies 
of the HTP. The Durbin-Watson d statistics of SPSS version 20.0 was used as a test 
for serial correlation of error terms. Shift in slope with p< 0.05 was considered 
as statistically significant. Results: There was an increasing trend for all ATC1 
groups prior the implementation of policies. The trends in systemic antienfec-
tives (J0), alimentary and metabolism (A0) and Respiratory system (R0) Central 
Nerveous System (N0) groups were negatively impacted from all policies except for 
RF. All policies impacted negatively the trend in cardiovascular system (C0) group. 
Implementation of RF had a significant positive impact on A0 and R0 group. Impact 
of RF was positive on C0 however it did not reach signifcance level. cOnclusiOns: 
Policy changes were very successful to control growth of top selling pharmaceuti-
cal groups while improving access to health. RF and CMS policies were the least 
effective cost containment measures
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Objectives: To compare the savings achieved by appraisal of the clinical and cost 
effectiveness of individual drugs by NICE’S Technology Appraisals for England & 
Wales with those due to price cuts under the Pharmaceutical Pricing Regulation 
Scheme 2000-2014. MethOds: Maximum and best estimates of savings attributable 
to the 512 technologies appraised and published by NICE to end 2013 with published 
reports of the PPRS. Published estimates of the cost of the Multiple Risk Sharing 
Scheme, the Cancer Drugs Fund and the End-of-Life criteria. Results: Savings 
attributable to NICE were relatively low. Few drugs were not recommended and of 
these, special schemes, funds and exceptions required by the governments of the 
day, reduced savings that might otherwise have resulted. The bulk of the savings 
due to NICE resulted from price cuts under Patient Access Schemes from 2009. 
Higher savings resulted from cross the board price cuts in the PPRS. cOnclusiOns: 
Health systems aiming to control pharmaceutical expenditure should consider both 
individual level appraisal of drugs as overall budget control of the branded prescrip-
tion drugs budget.
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Objectives: In 2003 Health Transformation Program and in 2006 Social Security 
Reform were launched in Turkey. At the end of the years 2009 and 2011 price cuts 
were done by the Government and between the years 2010-2012, there was a global 
budget implementation in Turkey. The top 100 medicines, annual average highest 
amount of sales of between 2008-2013, had one to four of the total pharmaceuti-
cal market value in 2013. We aimed to examine the status of original and generic 
medicines in the first 100 medicine’s and evaluate the effects of policy interven-
tions on these medicine sales. MethOds: While pharmaceutical sales data were 
obtained from the IMS Health-Turkey data base, prices and characteristics of medi-
cines were obtained from the Turkish Medicine and Medical Devices Agency data 
bases. Each group (original/generic medicines) was analyzed using TRAMO and 
SEATS method. Results: 78 medicines are original, 22 medicines are generic. In 
2009 compared to the previous year both generic and original medicine spending 
increased by respectively 16% and 20,9%. Between the years 2010-2012 compared 
to the previous year both generic and original medicines spending decreased by 
different ratios. In 2013 according to 2012, generic medicine spending decreased 
by 8.3% but original medicine spending increased by 7.9%. In 2013 total original 
medicine spending was 2888 million Turkish Liras (TL). This amount estimated to 
be 3050 million TL in 2014 and 3145 million TL in 2015. Generic medicines total 
spend was 501 million TL in 2013. This amount projected to be 510 million TL in 
2014 and 515 million TL in 2015. cOnclusiOns: Original medicines dominated the 
top 100 medicines. The total effect of the intervention is more negatively in generic 
medicines. At the end of 2013, it is understood that original medicines total amount 
have a tendency to increase.
